What is follicular dendritic cell sarcoma?
Follicular dendritic cell sarcoma (FDC sarcoma) is a rare cancer that grows from follicular dendritic cells. These are support cells found in the B-cell follicles of lymph nodes and other lymphoid tissue. Their normal job is to hold on to antigens (pieces of germs) and show them to B cells, helping the immune system make antibodies.
Despite the similar name, follicular dendritic cells are not true immune blood cells. They develop from connective tissue (stromal) cells. For this reason, the latest WHO classification places FDC sarcoma among the stroma-derived tumours of lymphoid tissues (Alaggio et al., 2022).
FDC sarcoma usually affects adults in middle age, with an average age of about 45-50 years. Men and women are affected about equally (Saygin et al., 2013).
About a third of tumours start in lymph nodes, most often in the neck. The rest grow outside lymph nodes, for example in the tonsil, throat, bowel, liver, spleen or the middle of the chest (mediastinum).
A special form, now called EBV-positive inflammatory follicular dendritic cell sarcoma, grows in the liver or spleen. It is linked to the Epstein-Barr virus and mainly affects women.
FDC sarcoma is usually treated with surgery, sometimes followed by radiotherapy. It often behaves like a low- to intermediate-grade sarcoma: it can come back and spread, but many people live for years (Chan et al., 1997).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Sarcoma of follicular dendritic (stromal) cells of lymphoid tissue |
| How common | Very rare; a few hundred cases described in the medical literature |
| Typical age | Adults; average about 45-50 years |
| Common sites | Neck lymph nodes, tonsil, throat, gut, liver, spleen, mediastinum |
| Key markers | CD21, CD23, CD35, clusterin, CXCL13 |
| Linked conditions | Hyaline vascular Castleman disease in some cases; EBV in the inflammatory type |
| Main treatment | Complete surgical removal, often with radiotherapy |
| Typical spread | Local recurrence; lymph nodes, lungs, liver |
| Outlook | Many people do well after complete removal; recurrence is common |
2. Causes and risk factors
The cause of FDC sarcoma is not known in most people. It is not inherited and not contagious.
| Factor | Notes |
|---|---|
| Castleman disease | Hyaline vascular (unicentric) Castleman disease is found in or near some tumours and may be a precursor |
| Epstein-Barr virus (EBV) | Found in the tumour cells of the inflammatory form in the liver and spleen |
| Sex | The EBV-positive inflammatory type is more common in women |
| Geography | The EBV-positive inflammatory type is reported more often in East Asia |
Gene changes
FDC sarcomas often carry changes in genes that control the NF-kappaB pathway, a signalling system involved in inflammation and cell survival. Common changes involve NFKBIA, CYLD and TNFAIP3, and many tumours lose the CDKN2A tumour suppressor gene (Griffin et al., 2016).
A minority carry the BRAF V600E mutation. These changes arise only in the tumour and are not passed on in families.
FDC sarcoma and Castleman disease
In a minority of cases, often quoted as about 1 in 10 to 1 in 5, the tumour occurs together with hyaline vascular Castleman disease, a non-cancerous overgrowth of lymph node tissue (Facchetti et al., 2021). Abnormal clusters of follicular dendritic cells in Castleman disease may, in rare cases, develop into FDC sarcoma.
The EBV-positive inflammatory type
This form looks and behaves differently from classic FDC sarcoma.
| Feature | EBV-positive inflammatory type | Classic FDC sarcoma |
|---|---|---|
| Main sites | Liver and spleen | Lymph nodes, tonsil, gut and other sites |
| Sex | Mostly women | Men and women equally |
| Microscope | Scattered tumour cells among many inflammatory cells | Sheets and whorls of tumour cells |
| EBV in tumour cells | Present | Absent |
| Behaviour | Usually slow-growing | Low to intermediate grade |
3. How does it look
The lump
| Feature | Description |
|---|---|
| Lymph node tumours | A painless, slowly growing lump, usually in the neck |
| Tonsil and throat | A mass on one side of the throat |
| Abdominal tumours | A large mass in the bowel wall, mesentery, liver or spleen |
| Size | Often 5 cm or more; abdominal tumours can be much larger |
| Edges | Usually well defined, but may grow into nearby tissue |
| Cut surface | Pink-tan, firm; sometimes with bleeding or dead areas in large tumours |
On scans
On CT or MRI, FDC sarcoma usually appears as a solid, well-defined mass that takes up contrast dye. Large tumours may have areas of dead tissue or calcium. On PET-CT, the tumour usually lights up. These findings are not specific, so a biopsy is needed.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Oval to spindle-shaped cells with pale pink cytoplasm and indistinct borders |
| Nuclei | Oval, with fine chromatin and small nucleoli; some cells have two nuclei |
| Pattern | Whorls, fascicles (bundles) and storiform (cartwheel-like) arrangements |
| Background | Small lymphocytes scattered among the tumour cells, often clustered around blood vessels |
| High-grade features | Marked nuclear atypia, many mitoses and necrosis in more aggressive tumours |
Special stains
| Marker | Result |
|---|---|
| CD21, CD23, CD35 | Positive (classic follicular dendritic cell markers) |
| Clusterin, CXCL13, podoplanin (D2-40) | Often positive |
| SSTR2 | Often positive |
| CD1a and langerin | Negative |
| Keratin | Usually negative |
| EBV (EBER) | Positive in the inflammatory type of liver and spleen |
FDC sarcoma is often misdiagnosed at first, because it can look like other spindle-cell tumours, thymoma, carcinoma or lymphoma (Facchetti et al., 2021).
4. Symptoms
Many people have few symptoms and notice only a slowly growing lump.
Common symptoms
- A painless lump in the neck, armpit or groin
- A lump on one side of the throat or a feeling of something stuck
- Difficulty swallowing or a muffled voice with tonsil tumours
- Tummy pain, fullness or a lump in the abdomen
- Tiredness
General symptoms
Some people, especially those with abdominal or EBV-positive tumours, develop:
- Fever
- Weight loss
- Night sweats
- Anaemia, causing tiredness and breathlessness
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Lymph nodes | New swollen glands |
| Lungs | Cough, breathlessness, chest pain |
| Liver | Pain under the right ribs, jaundice (rare) |
| Abdominal lining | Swelling of the tummy, bloating |
Rare immune problems
FDC sarcoma, particularly when linked with Castleman disease, can rarely be associated with paraneoplastic pemphigus, a severe blistering disease of the mouth and skin, and with myasthenia gravis, which causes muscle weakness.
When to seek medical advice
See a doctor if you have a lump that lasts more than 2-3 weeks, a growing throat or neck mass, or unexplained fever and weight loss.
5. Diagnosis
| Test | Purpose |
|---|---|
| Examination | Checks lymph nodes, throat and abdomen |
| Ultrasound, CT or MRI | Shows the size and position of the mass |
| Biopsy | A surgical (excision) biopsy or core biopsy; needle aspiration alone is rarely enough |
| Immunohistochemistry | CD21, CD23, CD35 and other markers confirm the diagnosis |
| EBV testing (EBER) | For liver and spleen tumours |
| PET-CT | Staging, to find other sites of disease |
| Blood tests | Blood count, liver and kidney function |
Because the tumour is rare and easily confused with other cancers, the sample should be reviewed by an expert haematopathologist or sarcoma pathologist.
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Interdigitating dendritic cell sarcoma | S100 positive; CD21 and CD23 negative |
| Histiocytic sarcoma | CD163 and CD68 positive; FDC markers negative |
| Thymoma | Keratin positive epithelial cells |
| Gastrointestinal stromal tumour | KIT and DOG1 positive |
| Inflammatory myofibroblastic tumour | ALK often positive; FDC markers negative |
| Lymphoma | B- or T-cell markers positive |
6. Treatment
Treatment is planned by a team with experience in rare lymphoid and sarcoma tumours.
Localised disease
| Treatment | Notes |
|---|---|
| Surgery | Complete removal with clear margins is the main treatment |
| Radiotherapy | Often given after surgery for large tumours, close margins or high-grade features |
| Chemotherapy after surgery | Not of proven benefit; sometimes considered for high-risk tumours |
In pooled analyses, people whose tumours were completely removed did best (Saygin et al., 2013). The benefit of added radiotherapy or chemotherapy has not been proven in trials, so the decision is made case by case.
Advanced or recurrent disease
| Treatment | Notes |
|---|---|
| Surgery for recurrence | Repeat surgery can control local recurrences or single metastases |
| Chemotherapy | Lymphoma-type (CHOP), sarcoma-type (ifosfamide, doxorubicin) or gemcitabine with docetaxel; responses vary (Jain et al., 2017) |
| Immunotherapy | Many tumours express PD-L1; checkpoint inhibitors have helped some patients |
| Targeted therapy | Being explored, for example BRAF inhibitors for BRAF V600E tumours |
| Clinical trials | Recommended where available |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Surgery for a neck node or tonsil | Usually a short hospital stay; most people eat and talk normally within days to weeks |
| Abdominal surgery | A larger operation with a hospital stay of about 1 week and a recovery of several weeks |
| Radiotherapy | Short daily sessions on weekdays, usually over 5-6 weeks |
| Chemotherapy | Given through a drip in cycles every 2-3 weeks, usually as a day patient |
| Immunotherapy | A drip every 3-6 weeks, with regular blood tests to check for side effects |
Side effects
| Treatment | Possible side effects |
|---|---|
| Neck or throat surgery | Pain, swallowing difficulty, voice change, numbness |
| Abdominal surgery | Pain, slow recovery of bowel function, wound problems |
| Radiotherapy | Skin soreness, tiredness; dry mouth or sore throat in the head and neck area |
| Chemotherapy | Low blood counts, infections, nausea, hair loss, tiredness |
| Immunotherapy | Tiredness, rash, and inflammation of the bowel, lungs, liver or glands |
7. Outlook (prognosis)
| Measure | Approximate figures |
|---|---|
| Local recurrence | About 1 in 4 to 1 in 3 |
| Distant spread | About 1 in 4, sometimes many years later |
| Long-term survival | Most people with localised disease are alive several years after treatment |
A pooled analysis of 462 cases confirmed that recurrence and spread are common, and that complete surgery is linked with the best results (Saygin et al., 2013). Chan and colleagues first showed that the tumour behaves more aggressively than once thought, and described features linked with a worse outcome (Chan et al., 1997). A large single-centre study found that outcomes varied widely and that many patients with localised disease lived for years (Jain et al., 2017).
Factors linked with a poorer outlook
- Tumour larger than 6 cm
- Abdominal location
- Coagulative necrosis
- High mitotic rate (many dividing cells)
- Marked cell atypia
- Incomplete removal
The EBV-positive inflammatory type in the liver or spleen usually behaves in a more indolent way.
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinical examination | Every 3-6 months for the first few years |
| CT, MRI or PET-CT | To detect recurrence at the original site or spread |
| Long-term checks | Continued for at least 5-10 years, because late recurrences occur |
9. Living with follicular dendritic cell sarcoma
- Keep all follow-up appointments, even if you feel well
- Check for new lumps in the neck, armpits and groin
- Report new symptoms such as cough, swallowing problems or tummy pain
- Ask for swallowing and speech therapy after head and neck treatment if needed
- Look after your mouth and teeth after radiotherapy to the throat
- Stay active with regular walking or gentle exercise to help recovery and energy levels
- Stop smoking, which improves healing and reduces the side effects of radiotherapy
- Seek support from rare cancer and sarcoma charities
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is FDC sarcoma a lymphoma? | No. It arises in lymphoid tissue but from support (stromal) cells, not lymphocytes |
| Is it the same as follicular lymphoma? | No. Follicular lymphoma is a B-cell cancer; the names are similar because both relate to lymph node follicles |
| Is it inherited? | No |
| Will I need chemotherapy? | Usually not if the tumour can be fully removed |
| Can it come back? | Yes, sometimes years later, so follow-up is important |
| Is it linked to Castleman disease? | In some people, yes |
| Why did the diagnosis take so long? | The tumour is rare and looks like several other cancers, so specialist stains and expert review are often needed |
| Can I have children after treatment? | Surgery and radiotherapy away from the pelvis usually do not affect fertility; ask about fertility preservation before chemotherapy |
11. Questions to ask your care team
- Has the diagnosis been confirmed with CD21, CD23 and CD35 stains?
- Was the tumour completely removed?
- Does the tumour have high-risk features?
- Would radiotherapy reduce my risk of recurrence?
- How often will I have scans, and for how long?
- Are there clinical trials I could join?
Resources
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Chan, J.K. et al. (1997) ‘Follicular dendritic cell sarcoma: clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized’, Cancer, 79(2), pp. 294-313.
- Facchetti, F., Simbeni, M. and Lorenzi, L. (2021) ‘Follicular dendritic cell sarcoma’, Pathologica, 113(5), pp. 316-329.
- Griffin, G.K. et al. (2016) ‘Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-kappaB regulatory genes’, Modern Pathology, 29(1), pp. 67-74.
- Jain, P. et al. (2017) ‘Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma’, British Journal of Haematology, 178(3), pp. 403-412.
- Saygin, C. et al. (2013) ‘Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series’, Critical Reviews in Oncology/Hematology, 88(2), pp. 253-271.
- National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.